Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy.

Patients with acute coronary syndrome (ACS) face a substantial risk of future adverse cardiovascular events, including recurrent ACS ([1][1],[2][2]). Because this risk is partly attributable to lipid-rich vulnerable plaque, high-intensity statin therapy is recommended as a secondary prevention